← FDA DRUG APPROVALS

FDA ANDA · ANDA077483

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

Sponsor: SUN PHARM INDS LTD

APPLICATION
ANDA077483
TYPE
ANDA
ORIGINAL APPROVAL
2005-09-08
LATEST ACTION
2019-11-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEDiscontinued
BENAZEPRIL HYDROCHLORIDE 20MG, HYDROCHLOROTHIAZIDE 12.5MG · TABLET · ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEDiscontinued
BENAZEPRIL HYDROCHLORIDE 5MG, HYDROCHLOROTHIAZIDE 6.25MG · TABLET · ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEDiscontinued
BENAZEPRIL HYDROCHLORIDE 20MG, HYDROCHLOROTHIAZIDE 25MG · TABLET · ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDEDiscontinued
BENAZEPRIL HYDROCHLORIDE 10MG, HYDROCHLOROTHIAZIDE 12.5MG · TABLET · ORAL

Approval history

2019-11-07Labeling · Supplement 10 · standardAP
2019-11-07Labeling · Supplement 9 · standardAP
2016-03-24Labeling · Supplement 8 · standardAP
2015-04-06Labeling · Supplement 7 · standardAP
2014-09-23Labeling · Supplement 6 · standardAP
2014-09-23Labeling · Supplement 5AP
2005-09-08OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →